青海地区藏族人群着色性干皮病基因D、谷胱甘肽-S-转移酶M1基因多态性与肝癌易感性的关系

目的 探讨青海地区藏族人群着色性干皮病基因D(XPD)、谷胱甘肽-S-转移酶(GST)M1基因多态性与原发性肝癌(PHC)易感性的关系. 方法 采用病例对照研究,选择青海地区藏族PHC患者及同期藏族健康体检者各102例,用PCR、变性高效液相色谱技术进行基因分型检测,以非条件logistic逐步回归模型进行PHC危险因素的多变量分析,比较不同基因型与PHC患病风险的关系.计数资料采用x2检验,以比值比(OR)及其95％可信区间(CI)表示相对危险度. 结果 吸烟、肉食、饮酒、HBV感染、直系亲属HBV感染、直系亲属肝癌等均进入logistic回归模型(α=0.05).XPD751C突变基因型在病例组和对照组的分布频率分别为21.6％和10.8％,组间差异有统计学意义(x2=4.374,P=0.036),罹患PHC的风险OR为2.275(95％CI为1.04～4.98).GSTM1空白基因型在病例组和对照组的分布频率分别为60.8％和44.1％,组间差异有统计学意义(x2=5.680,P=0.017);携带GSTM1空白基因型者患病风险是携带GSTM1非空白基因型者的1.963倍(95％ CI为1.124 ～ 3.428).将XPD751C基因突变和GSTM1空白联合基因型作为暴露因素,罹患肝癌的风险OR为3.030 (95％ CI为1.165 ～ 7.881);XPD751C突变基因型与HBV感染、饮酒、家族直系亲属肝癌等因素有交互作用.结论 吸烟、饮酒、肉食、HBV感染、直系亲属HBV感染、直系亲属患肝癌等是青海藏族人群罹患PHC的主要环境危险因素;XPD751C突变等位基因型、GSTM1空白基因型是青海藏族人群PHC的易感因素;携带XPD751C突变和GSTM1空白联合基因型的个体,比单个基因型患病风险显著增加;青海藏族人群携带XPD751C突变等位基因型的个体可分别与HBV感染、饮酒、家族直系亲属肝癌3种环境危险因素共同诱导PHC的发生.     

核苷酸切除修复基因ERCC1、XPD和XPC多态性与燃煤污染型地方性砷中毒的关系研究

目的 探讨核苷酸切除修复基因ERCCI、XPD、XPC不同基因型与燃煤污染型砷中毒发病风险的关系.方法 以贵州省兴仁县交乐村燃煤污染型砷中毒病区229例砷中毒患者作为病例组,以有相似生活习惯、无燃用高砷煤史的非砷暴露村大果朵村198名居民作为对照组,每人抽取外周静脉血约2 ml提取DNA,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术进行ERCC1 C8092A 、XPD Lys751 Gln、XPD Asp312Asn、XPD Arg156Arg、XPC P(AT+/-)多态位点检测.结果 病例组ERCC1 C8092A位点CA/AA基因型分布频率[ CA:29.78％ (67/225)、AA:10.67％ (24/225)]显著高于对照组[CA:23.08％( 45/195)、AA:5.13％ (10/195),x2=8.116,P＜0.05];其余各基因多态位点的基因型分布频率差异无统计学意义(x2值分别为5.649、4.394、0.865、1.490,P均＞0.05).携带ERCCI 8092CA+ AA、XPD Lys751Gln+ Gln751Gln 、XPD Asp312Asn+ Asn312Asn基因型个体分别较携带ERCC1 8092CC、XPD Lys751Lys、XPD Asp312Asp基因型个体发生砷中毒的风险升高1.780、1.681、1.790倍(95％CI分别为1.174～2.698、1.081～2.615和1.014～3.158,P均＜0.05);单一的XPD 基因Arg156Arg位点、XPC基因P(AT+/-)位点对砷中毒的发病风险没有影响(P均＞0.05).结论 核苷酸切除修复基因ERCC1 C8092A、XPD Lys751 Gln和Asp312Asn位点的多态性与燃煤污染型砷中毒的发病风险有关.     

DNA切除修复基因XPD在肝癌中遗传易感性的荟萃分析

目的 探讨DNA切除修复基因XPD基因多态性在中国人群原发性肝癌中的遗传易感性. 方法 检索中外数据库,获得有关XPD基因多态性与肝癌发病风险的病例对照研究资料进行Meta分析,得到合并的优势比(OR)和95％可信区间(95％CI). 结果 共纳入XPD基因多态位点相关文献6篇,累计病例3424例,对照3636例;在XPD基因多态位点751和312位点等位基因的OR (95％CI)分别为1.25 (0.70～ 2.24)和0.85 (0.58～ 1.25);在XPD基因多态位点751,与野生基因型Lys/Lys相比,(Lys/Gln+Gln/Gln)合并的OR(95％CI)为1.31(0.71 ～ 2.42);在XPD基因多态位点312位点,与野生基因型Asp/Asp相比,(Asp/Asn+Asn/Asn)合并的OR值(95％CI)为1.19 (0.73～ 1.95). 结论 XPD多态性遗传位点751和312不是中国人群原发性肝癌发病的风险因素.     

XRCC1和XPD单核苷酸多态性与非小细胞肺癌铂类药物化疗敏感性的关系

目的研究X线修复交叉互补基因1（XRCC1）和着色性干皮病基因（XPD）单核苷酸多态性与老年晚期非小细胞肺癌（NSCLC）铂类药物化疗敏感性关系。方法应用聚合酶链反应结舍限制性片段长度多态性（PCR-RFLP）的方法检测81例以铂类药物为主要化疗方案的NSCLC患者XRCC1 Arg399Gln和XPD Lys751Gin基因型多态性，采用非条件Logistic回归分析不同基因型与化疗疗效的关系。结果81例患者化疗总有效率为35．8％，其中完全缓解（CR）、部分缓解（PR）、稳定（SD）和进展（PD）患者分别为0、29、31、21例。携带至少1个XRCC1 399Arg等位基因的患者化疗敏感性是携带Gln／Gln基因型患者的4.52倍（OR=4．52，95％CI=1.11—18．38）。未发现XPD Lys751Gin遗传多态与化疗敏感性相关。结论XRCC1 Arg399Gln多态可能与晚期NSCLC铂类药物化疗敏感性有关。     

DNA修复基因XPC和XPG单核苷酸多态性与肝细胞癌易感性的关系

目的 探讨广西地区DNA修复基因XPC(Ala499Va1、Lys939G1n)和XPG(His1104Asp)单核苷酸多态性与肝细胞癌(HCC)易感性的关系.方法 采用以医院为基础的病例对照研究.经组织病理学确诊的HCC患者500例,相同地区,年龄、性别和民族频数匹配的非肿瘤患者507例.采用TaqMan MGB实时荧光定量PCR检测XPC和XPG基因多态性,比较不同基因型与HCC患病风险的关系.分别用t检验和X2检验对计量资料和计数资料进行统计分析;采用非条件的Logistic同归计算比值比(OR)及其95%可信区间(CI).结果 与XPC基因Ala499Va1位点CC基因型相比,CT或者TT基因型与HCC患病风险无相关性(校正OR=1.34,95%CI:0.85～2.12;校正OR=1.30,95%CI:0.68～2.51);与Lys939G1n位点AA基因理相比,AC或者CC基因型与HCC患病风险无相关性(校正OR=1.20,95%CI:0.78～1.85;校正OR=1.81,95%CI:0.88～3.73).与XPG基因His1104Asp位点CC基因型相比,CG或者GG基因型与HCC患病风险尢相关性(校正OR=0.85,95%CI:0.56～1.27;校正OR=1.12,95%CI:0.67～1.87).分层分析结果显示,与携带XPC基因Lys939G1n位点AA基因型女性相比,携带AC+CC基因型的女性患HCC的风险增加2.17倍(95%CI:01～4.64).结论 XPC基因Ala499Va1和Lys939G1n位点以及XPG基因His1104Asp位点SNP的单独效应可能与HCC易感性无相关性,但是XPC基因Lys939G1n位点C等位基因可协同增加女性患HCC的风险.     

东北地区汉族人群DNA修复基因XPD单核苷酸多态性与胃癌的相关性

目的:研究核苷酸切除修复基因XPD单核苷酸多态性与东北地区汉族人群胃癌风险的关系.方法:以聚合酶链反应-限制性片段长度多态性方法分析了238例胃癌患者标本XPD基因Asp312Asn和Lys751Gln多态性,比较不同基因型与胃癌风险的关系.结果:Lys751Gln多态在胃癌患者中的分布和正常对照组差异不显著,与胃癌风险无关.胃癌患者中Asp/Asn和Asn/Asn基因型频率明显高于正常对照组(P=0.041);与携带312Asp/Asp基因型者比较,携带至少1个312Asn等位基因者(即Asp/Asn和Asn/Asn基因型)罹患胃癌的风险增加1.901倍(95%CI:1.119-3.229).结论:XPD基因Asp312Asn多态是东北地区汉族人群胃癌遗传易感因素.     

COX-2基因多态性与结直肠癌发病风险的关系研究

目的 探讨环氧合酶-2(COX-2)-765G＞C、-1195G＞A、8473T＞C基因多态性与结直肠癌(CRC)遗传易感性的关系,同时评估COX-2基因多态性与某些因素共同作用对CRC发病风险的影响.方法 采用病例对照研究方法,入选CRC患者130例及健康非肿瘤人群120例.PCR-RFLP方法检测病例组和对照组COX-2基因的3个多态基因型,结果采用非条件logistic回归分析,用比值比(OR)及95％可信区间(CI)评估研究因素对疾病危险度的作用.结果 病例组COX-2-765G＞C、-1195G＞A、8473T＞C基因型频率与对照组间的差异均无统计学意义.根据体重指数(BMI)将研究对象分层后,发现-765GG基因型与CRC发病风险的相关性具有统计学意义,与正常BMI(＜23)相比,携带-765GG基因型且超重或肥胖者(BMI≥23)患CRC风险增高(OR=2.024,95％CI:1.089～3.760,P=0.024).此外,还发现吸烟可增加患CRC的风险,与不吸烟人群相比,吸烟人群中的8473TT基因型携带者患CRC的风险明显增高(OR=1.938,95％CI:1.021～3.677,P=0.042).结论 虽然COX-2 765G＞C、-1195G＞A、8473T＞C基因多态性与CRC遗传易感性之间没有相关性,但是携带-765GG基因型的高BMI人群或携带8473TT基因型的吸烟人群的CRC发生风险显著增高.对COX-2基因多态性位点的检测将有助于预防CRC的发生.     

髓过氧化物酶基因多态性与原发性高血压遗传易感性的研究

目的:研究髓过氧化物酶(MPO)基因多态性与原发性高血压(EH)之间的遗传易感性.方法:采用分子流行病学方法,应用聚和酶链反应检测法107例EH和97例健康对照MPO基因型,比较不同基因型之间的分布频率及95%可信区间(CI),分析MPO基因多态性与EH易感性的关系.结果:正常人群GG、GA、AA基因型频率分别为56 7%、40 2%和3 1%,EH组分别为70 1%、29 0%和0 9%.携带GG者患EH的风险是基因型为至少一个等位基因A者的1 79倍 (95%CI 1 005~3 186).结论:本研究人群MPO基因多态与EH遗传易感性相关,等位基因A对EH易感性有保护作用.     

XRCC1和XPD单核苷酸多态性预测晚期NSCLC铂类化疗敏感性的研究

目的探讨DNA损伤修复基因XRCC1和XPD单核苷酸多态性与晚期非小细胞肺癌(NSCLC)对铂类药物化疗敏感性的关系。方法以聚合酶链反应结合限制性片段长度多态性(PCR-RFLP)方法,检测166例以顺铂(DDP)为基础药物化疗的晚期NSCLC患者XRCC1 Arg194Trp和XPD Asp312Asn多态基因型,并比较不同基因型与化疗敏感性的关系。结果化疗总有效率(CR PR)为31.3%,其中CR2例,PR50例,SD70例,PD44例。携带至少1个XRCC1第194位密码子Trp等位基因患者化疗敏感性是携带Arg/Arg基因型患者的4.3倍(OR=4.32,95%CI=2.10~8.87,P=0.000);携带XPD第312位密码子Asp/Asp基因型患者化疗敏感性是携带至少1个Asn基因型患者的3.5倍(OR=3.49,95%CI=1.76~6.96,P=0.000)。联合分析这两个遗传多态性发现,尚不能认为XRCC1 Arg194Trp和XPD Asp312Asn多态性在NSCLC对铂类药物敏感性中存在联合作用(P>0.05)。结论XRCC1 Arg194Trp和XPD Asp312Asn单核苷酸多态性可能与NSCLC铂类药物敏感性有关。     

XRCC1单核苷酸多态性对非小细胞肺癌患者顺铂疗效的影响

目的探讨人类X射线交错互补修复基因1(XRCC1)单核苷酸多态性(SNP)与非小细胞肺癌(NSCLC)铂类药物化疗后预后的关系。方法采用MALDI-TOF-MS法检测204例经病理学确诊的接受铂类药物化疗的晚期NSCLC患者XRCC1(399)的基因型,并随机抽取5%的样本进行基因测序来验证该方法的准确性。比较不同基因型与铂类药物化疗后生存期的关系。结果 204例NSCLC患者中,部分缓解61例,疾病稳定116例,疾病进展27例;治疗有效率为29.9%,无效率为70.1%。携带XRCC1(399)G/G、G/A+A/A基因型的NSCLC患者铂类化疗后有效率分别为36.9%(38/103)和22.8%(23/101),两者比较差异有统计学意义(P<0.05)。XRCC1(399)G/G基因型患者对顺铂类药物的敏感性是G/A+A/A基因型患者的1.983倍(95%可信区间(CI):1.073~3.662,P=0.028)。携带XRCC1(399)G/G、G/A+A/A基因型的NSCLC患者铂类化疗后中位生存期(MST)、1年生存率及2年生存率分别为12.0月、52.4%、11.7%和10.0月、37.6%、3.0%,两者比较差异均有统计学意义(P<0.05)。结论 XRCC1(399)基因多态性与晚期NSCLC患者铂类药物化疗后的生存期有显著相关性,有可能成为铂类药物化疗后生存期的预测指标。     

Polymorphisms of the DNA repair gene xeroderma pigmentosum groups A and C and risk of esophageal squamous cell carcinoma in a population of high incidence region of North China

Aim Inherited polymorphisms of DNA repair genes may contribute to variations in DNA repair capacity (DRC) and genetic susceptibility to different cancers. The aim of this study was to determine whether single nucleotide polymorphisms (SNPs) of xeroderma pigmentosum group A (XPA) and XPC can influence the risk of esophageal squamous cell carcinoma (ESCC). Methods In this report, one SNP of XPA and three SNPs of XPC were genotyped by polymerase-chain reaction (PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP) assay in 327 ESCC patients and 612 healthy controls in a high incidence region of North China. Results Family history of upper gastrointestinal cancers (UGIC) may increase the risk of developing ESCC. The overall genotype and allelotype distributions of XPA A23G in ESCC patients were significantly different from that in healthy controls (P < 0.05). The A/G + G/G genotype significantly decreased the risk of developing ESCC compared with A/A genotype. When stratified for family history of UGIC, compared with A/A genotype, A/G + G/G genotype significantly decreased the risk of ESCC in groups with negative history of UGIC. The overall genotype and allelotype distributions of XPC intron 9 PAT^+/- and exon 15 Lys939Gln and exon 8 Val499Ala in ESCC patients were not significantly different from that in healthy controls (P > 0.05). When stratified for smoking status and UGIC family history, compared with A/A genotype, C/C genotype of exon 15 Lys939Gln significantly increased the risk of developing ESCC in non-smoker group. Conclusions We concluded that XPA23 polymorphism may be useful markers for identifying individuals at risk of developing ESCC. C/C genotype of XPC exon 15 may be one of the factors that affect the risk of developing ESCC in nonsmoking population in the high incidence region of China.     

The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China.

AIM: High incidence rates of hepatocellular carcinoma (HCC) in Guangxi, China, are primarily due to heavy aflatoxin B1 (AFB1) exposure via corn and groundnut consumption. This study was designed to examine the polymorphisms associated of three carcinogen-metabolizing genes (namely: GSTM1, GSTT1, and HYL1*2) and one DNA-repair gene (namely: XRCC1), and investigate their role as susceptibility markers for HCC. METHODS: We conducted a case-control study including 257 cases of cancer and 649 hospital-based age, sex, ethnicity, and hepatitis B virus infection-matched controls to examine the role of genetic polymorphisms of four genes (GSTM1, GSTT1, HYL1*2, and XRCC1) in the context of HCC risk for the Guangxi population. Genomic DNA isolated from 2ml whole blood was used to genotype GSTM1, GSTT1, HYL1*2, and XRCC1 by means of polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis. RESULTS: GSTT1-null genotype was not significantly associated with the risk of HCC, but GSTM1-null genotype [adjusted odds ratio (OR)=2.29, 95% confidence interval (CI)=1.59-3.31], HYL1*2 genotypes with 113 His allele (namely: YH/HH, adjusted OR=2.55, CI=1.78-3.65), and XRCC1 genotypes with 399 Gln allele (namely: AG/GG, adjusted OR=2.47, CI=1.72-3.54) increased the HCC risk. Compared with those individuals who did not express any putative risk genotypes as reference (OR=1), individuals featuring all of the putative risk genotypes [GSTM1-null, HYL1*2-YH/HH, and XRCC1-AG/GG] did experience a significantly greater cancer risk (adjusted OR=10.83, CI=5.44-21.59, P(interaction)<0.01). Additionally, the risk of HCC did appear to differ more significantly among individuals featuring risk genotypes and high-level or long-term AFB1 exposure, whose adjusted ORs (CIs) were 52.44 (17.51-157.08) and 326.93 (38.58-2770.52), respectively. CONCLUSIONS: The results suggest that carcinogen metabolism and DNA-repair pathways may simultaneously modulate the risk of HCC for Guangxi population, and, particularly for these having high-level or long-term AFB1 exposure.     

Prognostic importance of DNA repair gene polymorphisms of <Emphasis Type="Italic">XRCC1</Emphasis> Arg399Gln and <Emphasis Type="Italic">XPD</Emphasis> Lys751Gln in lung cancer patients from India

Purpose Inter individual variation in lung cancer susceptibility may be modulated in part through genetic polymorphisms in the DNA repair genes, especially the genes involved in the Base Excision Repair (BER) and nucleotide excision repair (NER) pathway. Two of the genetic polymorphisms, XRCC1Arg399Gln and XPD Lys751Gln have been extensively studied in the association with lung cancer risk, although published studies have been inconclusive. Methods In order to verify the role of the common variant alleles in the XPD gene, we have genotyped 211 lung cancer patients and 211 healthy controls using PCR-RFLP assays in a hospital based, case-control study in an Indian population. Logistic regression models were fit to examine the relationship between the log odds of lung cancer and each covariate. Overall Survival in relation to various genotypes and clinicopathological factors were analyzed using Kaplan Meier estimates and hazard ratios were calculated using Cox Regression analysis. Results The carriers of XRCC1 399 AA genotypes were at higher risk of lung cancer (OR = 2.1, 95% CI:1.224–3.669, P = 0.007) than carriers of GG genotype. Subjects carrying 751 AC genotype were at an increased risk of carcinoma of the lung (OR = 1.8; 95% CI:1.233–2.807, P = 0.003) than subjects with AA genotypes. Compared to the XRCC1 399 GG/ XPD 751 AA reference genotype, the combined variants, XRCC1 399 GG/ XPD 751 AC+CC (OR = 1.9, 95% CI: 1.037–3.481), P = 0.03), XRCC1 399 GA+AA/ XPD 751 AA (OR = 1.7, 95% CI: 1.020–2.833, P = 0.04), XRCC1 399 GA+AA/XPD 751 AC+CC (OR = 2.7, 95% CI: 1.582–4.864, P = 0.01), had significantly higher odds ratios. Increasing numbers of either XPD or XRCC1 variant alleles were associated with shorter overall survival, the risk being significant for the XRCC1 gene polymorphism (P = 0.01 by log-rank test). The hazard of dying was significant for the XRCC1 399 AA genotype (HR = 3.04, 95%CI: 1.393–6.670, P = 0.005). Higher tumour stage also came out as significant predictors of patient death. Conclusions These findings suggest that genetic polymorphisms in the DNA repair genes may modulate overall lung cancer susceptibility and that pathological stage and XRCC1 Arg399Gln independently predicted overall survival among Indian lung cancer patients.     

遵义人群载脂蛋白A5 c.553G/T基因多态性与混合型高脂血症的相关性研究

目的 探讨遵义人群载脂蛋白A5(ApoA5)基因c.553G/T位点多态性与混合型高脂血症的相关性.方法 收集222名遵义地区人群静脉血标本,其中混合型高脂血症组100例,正常对照组122名,用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术检测两组标本ApoA5基因c.553G/T位点多态性,分析混合型高脂血症组和正常对照组中基因型频率和基因频率分布规律,及其与混合型高脂血症的关系.结果 ApoA5 c.553G/T位点基因型频率和基因频率在混合型高脂血症组与正常对照组差异有统计学意义(x2=12.081,P=0.001;x2=17.469,P＜0.001);通过Logistic回归校正年龄、性别、血糖后,T等位基因携带者(TT+ GT基因型)患高脂血症的风险较GG基因型携带者增加(OR=6.042,95％CI:1.962～18.607,P=0.002).结论 ApoA5 c.553G/T位点多态性与遵义地区人群混合型高脂血症发病存在一定相关性,ApoA5 c.553T等位基因可能是混合型高脂血症的独立危险因素.     

ABCA1启动子区及7外显子基因突变对汉族人群高密度脂蛋白胆固醇水平的影响

目的研究汉族人群ABCA1启动子区-565C/T及7外显子G1051A基因多态性对HDL-C水平的影响。方法应用连接酶检测反应法对519例冠心病患者(冠心病组)及541例同期住院或体检者(对照组)测试-565C/T及G1051A基因型,生化检测HDL-C水平,分析HDL-C水平与不同基因型的关系。结果 -565C/T的CC、CT、TT不同基因型的HDL-C水平分别为(1.19±0.81)mmol/L、(1.14±0.28)mmol/L和(1.12±0.28)mmol/L,无显著差异(P=0.44);G1051A的GG+GA、AA不同基因型的HDL-C水平分别为(1.18±0.61)mmol/L和(1.29±0.27)mmol/L,无显著差异(P=0.52);logistic回归模型分析显示,校正年龄、性别、吸烟后,A等位基因系冠心病保护性因素(OR=0.428,95% CI:0.227～0.603,P=0.009)。结论 ABCA1-565C/T及G1051A 2种单核苷酸多态性与HDL-C水平无相关性;G1051A的A等位基因系冠心病保护性因素。     

谷氨酰-半胱氨酸连接酶催化亚基C-129T和修饰亚基G-23T多态性与冠心病的关系

目的 探讨谷氨酰-半胱氨酸连接酶催化亚基（GCLC）C-129T多态性和修饰亚基（GCLM）G-23T多态性与冠心病遗传易感性的关系。方法 采用聚合酶链反应-限制性片段长度多态方法,检测212例冠心病与218例对照的GCLCC-129T和GCLMG-23T基因型分布及差异。结果 冠心病组中GCLC-129T等位基因频率显著高于对照组（P〈0．01）,GCLC-129T的冠心病发病风险是-129C的2．38倍（95％CI：1．25～4．54）。与GCLC-129CC基因型相比,GCLC-129CT基因型的冠心病发病风险显著增加至2．14倍（95％CI：1．08～4．24,P〈0．05）,GCLC-129T等位基因携带者（CT、TT基因型）患冠心病的风险显著增加至2．28倍（95％CI：1．16～4．49,P〈0．05）。冠心病组中GCLM-23T等位基因频率显著低于对照组（P〈0．01）,GCLM-23T的冠心病发病风险是．23G的0．59倍（95％CI：0．42～0．82）。与GCLM-23GG基因型相比,GT、Tr基因型和-23T等位基因携带者（GT、Tr基因型）的冠心病发病风险分别为0．71倍（95％CI：0．47～1．08,P〉0．05）、0．18倍（95％CI：0．06～0．55,P〈0．01）和0．61倍（95％CI：0．42～0．92,P〈0．05）。结论 GCLCC-129T多态性可能是冠心病的一个遗传易感因素,而GCLMG-23T多态性可能是冠心病的一个遗传保护因素。     

胰蛋白酶原基因reflNG4599多态性与汉族胰腺癌遗传易感性的关系

目的探讨福建地区汉族胰腺癌患者外周血胰蛋白酶原(protease serine 1,PRSS1)基因reflNG4599单核苷酸多态性与胰腺癌风险的关系。方法采用聚合酶链反应(polymerase chain reaction,PCR)技术,对159例胰腺癌患者和368例正常对照者的PRSS1基因reflNG4599多态性进行基因型分析,统计胰腺癌组和正常对照组不同PRSS1基因型的基因频率,使用OR及95%CI对各基因型携带者发生胰腺癌相对风险度进行评估,同时比较各组不同基因型血清胰蛋白酶浓度的差异性。结果单变量Logistic回归分析显示PRSS1基因reflNG4599 T/C基因型与胰腺癌发生的风险相关(OR=1.58,95%CI:1.52~1.64);胰腺癌组血清胰蛋白酶浓度是正常对照组的4.92倍,且胰腺癌组中T/C杂合基因型携带者的血清胰蛋白酶浓度高于T/T和C/C纯合基因型者,分别为1.22倍和1.60倍。结论 PRSS1基因reflNG4599 T/C基因型与胰腺癌遗传易感性相关,血清胰蛋白酶可以作为胰腺癌的新型标志物。     

微小RNA-146a C＞G多态性与缺血性卒中风险:汇总分析

目的 探讨微小RNA-146a(microRNA-146a,miR-146a)C＞G多态性与缺血性卒中的关联性.方法 全面检索2016年2月以前发表的miR-146a C＞G多态性与缺血性卒中关系的病例对照研究,应用Stata 12.0软件包进行汇总分析,利用优势比(odds ratio,OR)和95％可信区间(confidence interval,CI)评价miR-146a C＞G多态性与缺血性卒中风险的关联强度.结果 共纳入8篇文献,病例组2 891例,对照组4 019例,入选文献无明显发表偏倚.在总体人群中,显性模型(GG+ CG对CC:OR 1.011,95％ CI0.863～1.185;P=0.889)、隐性模型(GG对CG+ CC:OR 0.999,95％ CI0.761 ～1.311;P=0.994)、杂合子模型(CG对CC:OR1.052,95％CI0.943～ 1.173;P=0.368)、纯合子模型(GG对CC:OR1.114,95％ CI0.819 ～ 1.515;P=0.491)和等位基因模型(G/C:OR1.062,95％ CI0.919～1.227;P=0.413)均未显示miR-146a C＞G多态性与缺血性卒中风险存在显著相关性.亚组分析显示,miR-146a C＞G多态性与大动脉粥样硬化性和小动脉闭塞性卒中的发病风险亦无显著相关性.结论 根据目前的文献,miR-146a C＞G多态性可能与缺血性卒中风险无显著关联性.